Top Stories
-
Columbia Psychiatry is among the principal investigators in biotech Compass Pathways study of more than 200 patients.
Topic
-
Source:
New York Times"The unbridled enthusiasm and commercial momentum generated by psychedelics are excessive and ill advised until we have more sound research," writes Dr. Jeffrey Lieberman.
Topic
-
Source:
WHYYAfter a decades-long hiatus, researchers are taking a fresh look at the potential of psychedelics in therapy.
Topic
-
Source:
MedscapeEcstasy "needs to be looked at in a very careful and rigorously controlled way to accrue evidence showing what it can do and what its potential liability is," says Dr. Jeffrey Lieberman.
Topic
